. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain. 2021 Dec 17; PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Atomoxetine

News

  1. Are Mid-Life Depression and Anxiety Early Signs of Alzheimer’s?